Почетна › Множен миелом › Округ Колумбија › Washington
Клинички испитувања за Множен миелом во Washington, DC
22 студии за Множен миелом бараат учесници на локации во и околу Washington (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Се регрутираФаза 1
- National Institutes of Health Clinical Center, Bethesda · на 7 милји
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Се регрутираФаза 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Се регрутираНабљудувачка студија
- National Institutes of Health Clinical Center, Bethesda · на 7 милји
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Се регрутираФаза 2
- National Institutes of Health Clinical Center, Bethesda · на 7 милји
Tissue Collection for Studies of Lymph Cancer
Се регрутираНабљудувачка студија
- National Institutes of Health Clinical Center, Bethesda · на 7 милји
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Се регрутираФаза 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · на 7 милји
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Се регрутираФаза 3
- Center for Cancer and Blood Disorders, Bethesda · на 7 милји
18F-Fluciclovine PET/CT in Multiple Myeloma
Се регрутираФаза 2
- National Institutes of Health Clinical Center, Bethesda · на 7 милји
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Се регрутираФаза 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · на 7 милји
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Се регрутираФаза 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
Се регрутираНабљудувачка студија
- National Institutes of Health Clinical Center, Bethesda · на 7 милји
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Се регрутираФаза 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Се регрутираФаза 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Се регрутираФаза 2
- GSK Investigational Site, Bethesda · на 7 милји
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Се регрутираФаза 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Се регрутира
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · на 7 милји
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Се регрутираФаза 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · на 7 милји
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Се регрутираФаза 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Се регрутираФаза 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Се регрутираФаза 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Испитувања за Множен миелом во други градови
- New York City, NY60 студии
- Boston, MA42 студии
- Atlanta, GA42 студии
- Houston, TX38 студии
- Durham, NC37 студии
- Nashville, TN32 студии
- Denver, CO27 студии
- Rochester, MN24 студии
- St. Louis, MO24 студии
- Columbus, OH24 студии
- Baldwin Park, CA23 студии
- Edison, NJ22 студии
Други студии во Washington
- Рак (сите типови)58 студии
- Рак на бели дробови со не-мали клетки55 студии
- Рак на дојка46 студии
- Метастатски карцином43 студии
- Рак на бели дробови41 студија
- Рак на простата38 студии
- Дебелина33 студии
- Колоректален карцином29 студии
- Кардиоваскуларни болести28 студии
- Рак на бешиката26 студии
- Акутна миелоидна леукемија24 студии
- Карцином на јајниците23 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.